oral, first-in-class CHIT1/AMCase chitinase inh.

for sarcoidosis/lung fibrosis, Ph. Ib complete

from opt. of literature molecule

J. Med. Chem., Oct. 20, 2020

OncoArendi Therapeutics SA, Warsaw, PL

OATD-01 (OncoArendi Therapeutics oral, first-in-class CHIT1/AMCase chitinase inhibitor clinical candidate)


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks